Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001388574 | SCV001589621 | pathogenic | Hereditary hemochromatosis | 2023-08-23 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asp699Argfs*92) in the TFR2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 103 amino acid(s) of the TFR2 protein. For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the TFR2 protein in which other variant(s) (p.Ile710Alafs*80) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with TFR2-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.007%). |
Baylor Genetics | RCV003473987 | SCV004203664 | likely pathogenic | Hemochromatosis type 3 | 2024-02-03 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV003473987 | SCV005674093 | likely pathogenic | Hemochromatosis type 3 | 2024-06-04 | criteria provided, single submitter | clinical testing |